Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Exothera.

    Client Virtual Booth

    EXOTHERA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Exothera
    Belgium Flag
    Country
    Country
    Belgium
    Address
    Address
    Avenue de Tervueren 270, 1150 Brussels
    Telephone
    Telephone
    +32 (0) 2 319 58 36
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://exothera.world/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Remedium and Exothera Partner On Scale-up And Demonstration Runs For AAV2-FGF18

    Details:

    Remedium and Exothera will demonstrate the industrialization potential of Remedium’s RMD 1101 (AAV2-FGF18). Remedium’s lead candidate is the only disease modifying gene therapy based on the clinically proven regenerative mechanism of FGF18 for the treatment of rheumatology.


    Lead Product(s): RMD 1101

    Therapeutic Area: Musculoskeletal Product Name: RMD 1101

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Remedium

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration March 22, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Valo Therapeutics Selects Exothera to Develop Large-Scale Oncolytic Adenovirus Manufacturing

    Details:

    VALO-D102 is a fundamental component of the company’s proprietary PeptiCRAd (peptide-coated Conditionally Replicating Adenovirus) immuno-oncology platform. PeptiCRAd combines two cancer immunotherapy approaches: an oncolytic Adenovirus and a peptide vaccine.


    Lead Product(s): VALO-D102

    Therapeutic Area: Oncology Product Name: VALO-D102

    Highest Development Status: DiscoveryProduct Type: Large molecule

    Recipient: Valo Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement January 11, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Rokote Laboratories Selects Exothera For GMP Manufacturing of Its Second-​generation Coronavirus Vaccine

    Details:

    The FINCoVac vaccine is designed to program the nasopharyngeal cells to produce immune response-inducing modified SARS-CoV-2-viral spike protein. FINCoVac 2.0 represents an easy-to-administer booster for those who are already fully vaccinated with other coronavirus vaccines.


    Lead Product(s): FINCoVac 2.0

    Therapeutic Area: Infections and Infectious Diseases Product Name: FINCoVac 2.0

    Highest Development Status: PreclinicalProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Rokote Laboratories

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership April 01, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    CyanVac Selects Exothera for the Development and GMP Manufacturing of Its Covid-19 Intranasal Vaccine Candidate for Phase III Clinical Trial

    Details:

    Exothera will be responsible for the fast-track development of a manufacturing process for CyanVac’s COVID-19 vaccine candidate, CVXGA1, using the unique scale-X™ platform.


    Lead Product(s): CVXGA1

    Therapeutic Area: Infections and Infectious Diseases Product Name: CVXGA1

    Highest Development Status: PreclinicalProduct Type: Vaccine

    Partner/Sponsor/Collaborator: CyanVac

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration March 24, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search